NCT07398326 2026-02-09
Anlotinib Combined With Sintilimab as First-line Treatment for Advanced Non-liver Metastatic Colorectal Cancer
Shanghai Changzheng Hospital
Phase 2 Recruiting
Clinical Trials
5 trialsNCT05229003 2024-07-03
Irinotecan Plus Anlotinib or Further in Combination With Penpulimab for Second-line Treatment of mCRC
Fudan University
Phase 2 Recruiting
NCT04271813 2024-04-23
Anlotinib Plus Sintilimab as First-line Treatment for Patients With Advanced Colorectal Cancer (APICAL-CRC)
Shanghai Changzheng Hospital
Phase 2 Completed
NCT04970914 2022-03-08
ALTER-C003
Peking Union Medical College Hospital
Phase 2 Unknown
NCT02332499 2019-05-21
ALTER0703
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2/3 Completed